Quick answer:
Spravato (esketamine) is not FDA-approved for chronic pain. It’s approved only for treatment-resistant depression. Some clinicians use it off-label for pain when depression is also present, and ketamine-class research shows real signals for neuropathic and centralized pain specifically. If your pain comes with treatment-resistant depression, it’s worth a conversation. If pain is your only diagnosis, IV ketamine has a deeper research base.
If you’ve spent years cycling through physical therapy, nerve blocks, and medications that either stop working or come with a list of side effects longer than the relief they provide, it’s reasonable to start looking past the standard playbook. Chronic pain that doesn’t respond to conventional treatment is exhausting in a way that’s hard to explain to anyone who hasn’t lived with it, and it’s why more people are asking a very specific question: does Spravato help with pain?
The honest, direct answer: Spravato (esketamine) is not FDA-approved for chronic pain. It’s approved only for treatment-resistant depression and depression with suicidal ideation. But a growing, genuinely interesting body of research on esketamine and related ketamine-based treatments is looking specifically at pain, particularly neuropathic and centralized pain conditions, and the early findings are worth understanding in detail rather than in vague, uncited generalities. This guide walks through what the actual research says, how Spravato and pain relief are connected biologically, how it compares to ketamine nasal spray for pain more broadly, and what a realistic treatment path looks like.
What is Spravato and how does it work?
Spravato is the brand name for esketamine, a ketamine derivative delivered as a nasal spray. The FDA approved it in 2019 for treatment-resistant depression, initially only alongside an oral antidepressant. In January 2025, the FDA expanded that to standalone monotherapy, the first ever approved for the condition (Johnson & Johnson). It’s still given only in certified clinical settings under supervision, and still not approved for pain.
Unlike traditional antidepressants, which primarily target serotonin, esketamine works by blocking NMDA (N-methyl-D-aspartate) receptors in the brain. This is the mechanism worth paying attention to, because NMDA receptors are involved in both mood regulation and pain signal transmission, which is exactly why researchers have started investigating esketamine’s effects beyond depression. Blocking these receptors increases glutamate activity and appears to support neuroplasticity, changes linked to both faster mood improvement and altered pain processing (Ma et al., Pain Research and Management, 2023).
Does Spravato help with pain? What the research shows
This is the core question, so here’s what current evidence actually supports rather than implies.
Direct research on Spravato specifically for pain is still limited. No large-scale clinical trials have evaluated esketamine as a primary chronic pain treatment. That said, several related research threads point in a consistent direction:
- The most Spravato-specific data comes from its depression trials, not pain trials. Johnson & Johnson states plainly that Spravato has not been studied and is not indicated for pain, but in TRANSFORM-2 at Day 28, 35.6% of patients on Spravato plus an oral antidepressant reported pain and discomfort impairment on the EQ-5D-5L scale, versus 54.0% on placebo. That’s a real difference, but it’s a quality-of-life measure in people treated for depression, not a pain endpoint.
- A 2022 systematic review and meta-analysis of randomized controlled trials found that adding ketamine to standard treatment produced a statistically significant reduction in neuropathic pain compared to standard treatment alone, though the benefit came with a real tradeoff in side effects, particularly psychedelic-type effects during administration (Guimarães Pereira et al., Journal of Pain Research, 2022).
- Esketamine specifically, not just racemic ketamine, has demonstrated efficacy for chronic pain and especially refractory neuropathic pain in clinical use, though researchers note its analgesic effect is short-lived after a single dose, which is part of why sustained-release delivery methods are an active area of research (Zhou et al., International Journal of Nanomedicine, 2023).
- A narrative review from Stanford and Emory pain medicine researchers examined ketamine’s use in Complex Regional Pain Syndrome (CRPS) specifically, noting that brief low-dose infusions tend to produce short-lived relief, while different dosing protocols are being studied for longer-lasting effects (Anesthesiology Clinics, 2023).
Where the evidence is strongest:
| Pain condition | Current evidence strength | What research suggests |
| Neuropathic pain | Moderate | Meta-analysis data shows statistically significant improvement with ketamine-class treatment |
| Complex Regional Pain Syndrome (CRPS) | Emerging | Reviewed specifically in pain medicine literature; dosing protocols still being refined |
| Fibromyalgia | Early | Mentioned in case-level and mechanism research; limited controlled trial data |
| Chronic migraine | Early | Anecdotal and mechanism-based interest; not yet backed by dedicated trials |
| General chronic pain (unspecified) | Preliminary | Reflects the broader ketamine-for-pain literature more than esketamine-specific data |
The honest summary: ketamine-class treatment, including esketamine, shows real signal for neuropathic and centralized pain conditions specifically, not chronic pain as a blanket category. That distinction matters, and any clinic that tells you otherwise isn’t representing the research accurately.
Spravato and anxiety: Why the pain-mood connection matters
Chronic pain rarely travels alone. It frequently overlaps with anxiety and depression, sharing biological pathways involving inflammation, stress hormone regulation, and altered central pain processing. This overlap is part of why Spravato for anxiety has become its own area of clinical interest, and it’s directly relevant to the pain conversation.
In Spravato’s original Phase 3 clinical trials for treatment-resistant depression, a notably high percentage of participants, 62% to 80%, had moderate to severe anxiety symptoms at baseline. A post hoc analysis of that trial data found meaningful improvement in anxiety symptoms among patients treated with Spravato alongside a newly initiated antidepressant (Daly et al., 2019, cited via Janssen’s clinical resource on Spravato and comorbid anxiety). Worth noting directly: Spravato and OCD is a separate and distinct research question. Patients with a current OCD diagnosis were excluded from the core depression trials, so Spravato OCD data comes from separate, still-developing research rather than the same evidence base.
What this means practically: for patients whose chronic pain is compounded by co-occurring anxiety or depression, Spravato’s effect on mood may provide a meaningful secondary benefit even when pain itself isn’t the primary target, since untreated anxiety and depression are well known to intensify how the brain perceives and processes pain signals.
How does Spravato make you feel?
Understanding the actual experience matters for anyone weighing this option. Spravato sessions happen entirely in a certified clinical setting; the medication cannot be taken home. During a session, most patients report:
- A sense of dissociation or feeling mentally “distant” for 20 to 40 minutes
- Mild dizziness or lightheadedness
- Changes in perception of time or surroundings
- Temporary increases in blood pressure, which is why vital signs are monitored throughout
These effects typically resolve within the required two-hour monitoring window after each dose. Many patients describe the experience as unusual but not distressing, and effects on mood or pain perception can begin to emerge within hours to days, though the full benefit generally builds over several weeks of treatment.
Why isn’t Spravato FDA-approved for chronic pain?
Spravato’s 2019 approval was based on clinical trials designed specifically around treatment-resistant depression, not pain. Using it for chronic pain is what’s known as off-label use, meaning a licensed provider is prescribing an FDA-approved medication for a condition outside its official approval, based on clinical judgment and emerging evidence rather than an FDA-reviewed indication for that specific use.
Off-label prescribing is common and legal in psychiatry and pain medicine, but it does mean:
- Insurance coverage for pain-specific use may vary or may not apply at all
- The strength of evidence is inherently earlier-stage than for an approved indication
- It should only be considered under the guidance of a provider experienced in both the medication and your specific pain condition
Who might be a candidate?
Spravato for chronic pain is most often considered for people who:
- Have tried standard pain treatments (physical therapy, medications, nerve blocks) without adequate relief
- Have a neuropathic or centralized pain condition specifically, rather than primarily inflammatory or mechanical pain
- Have co-occurring treatment-resistant depression or significant anxiety alongside their pain
- Are not on standard opioid pain management, or are actively working to reduce it
Safety, contraindications, and what to know before starting
Because esketamine is a Schedule III controlled substance and can affect blood pressure and consciousness, Spravato is administered only in REMS-certified clinics with required post-dose monitoring (FDA prescribing information). It may not be appropriate for people with:
- Uncontrolled high blood pressure
- A history of psychosis
- Severe cardiovascular disease
- Pregnancy or breastfeeding (esketamine has not been studied as safe in these populations)
A full medical and psychiatric evaluation is required before starting treatment, and this should always happen with a licensed provider who can review your complete history.
Spravato for chronic pain treatment in DFW: Why NeuroGlow
If you’re in Dallas-Fort Worth and standard pain treatment hasn’t worked, you deserve care from a team that treats this evidence honestly, not one that oversells an off-label treatment as a guaranteed fix. NeuroGlow is a board-certified, psychiatrist-led mental wellness clinic serving DFW from three locations in Fort Worth, McKinney, and Flower Mound, with more than 1,000 patients treated and over 5,000 treatments delivered across the metroplex.
What sets NeuroGlow apart for patients exploring Spravato for chronic pain:
- Physician-led evaluation, not a sales conversation. Every treatment plan starts with a real assessment of your pain history, prior treatments, and whether esketamine is genuinely appropriate for your specific condition, not a blanket recommendation.
- Deep experience with both Spravato and IV ketamine therapy, so your provider can talk through which delivery method fits your situation rather than defaulting to whichever one the clinic happens to offer.
- Honest handling of off-label status. We’ll tell you directly what the research does and doesn’t yet show, and what that means for your specific case and insurance coverage.
- Insurance support built in. The team verifies your insurance benefits for free and accepts major plans including Aetna, Cigna, Blue Cross Blue Shield of Texas, UnitedHealthcare, and TRICARE. See full pricing details.
- Care for the whole picture. When chronic pain overlaps with depression, anxiety, or PTSD, treatment is planned around all of it, not just the pain in isolation.
If you’ve been researching Spravato for chronic pain and want a straight answer about whether it’s right for your situation, book a free consultation to talk it through with a provider who will give you the real picture, not just the hopeful one.
FAQs
Does Spravato help with pain?
Spravato is not FDA-approved for pain, but emerging research on esketamine and related ketamine-class treatments shows meaningful signal specifically for neuropathic and centralized pain conditions. It’s considered off-label and works best as part of a broader, provider-guided treatment plan.
Is there research on ketamine nasal spray for pain specifically?
Most controlled trial data comes from IV ketamine rather than the nasal spray form, though esketamine nasal spray has shown efficacy for refractory neuropathic pain in clinical use, with researchers actively studying delivery methods that extend its short-lived analgesic effect.
Does Spravato help with anxiety too?
Spravato is approved only for treatment-resistant depression, but clinical trial data shows meaningful improvement in comorbid anxiety symptoms among patients treated for depression, which is relevant since anxiety and chronic pain frequently compound each other.
How does Spravato make you feel during treatment?
Most patients experience temporary dissociation, mild dizziness, and altered perception for 20 to 40 minutes after dosing, monitored in-clinic for at least two hours. These effects are usually not distressing and resolve the same day, but even so, the label requires no driving until the next day, after a restful night’s sleep.
Is Spravato the same as IV ketamine for pain?
No. Both block NMDA receptors and are used off-label for pain, but IV ketamine has a longer research history in pain medicine specifically, while Spravato’s approval and trial data center on depression, with pain research still developing.
Can Spravato help with OCD?
Spravato is not approved for OCD, and patients with an active OCD diagnosis were excluded from its core depression trials. Research into esketamine for OCD is a separate, earlier-stage area of study.
Who is not a good candidate for Spravato?
People with uncontrolled high blood pressure, a history of psychosis, severe cardiovascular disease, or who are pregnant or breastfeeding are generally not candidates. A full evaluation determines eligibility.
Will insurance cover Spravato for chronic pain?
Generally not when pain is the billed diagnosis, since Spravato isn’t FDA-approved for pain. Coverage is typically approved on the basis of treatment-resistant depression, with any pain benefit being secondary. NeuroGlow verifies your benefits for free before treatment.
How long does a Spravato session take?
Plan for about two to two and a half hours per visit. Dosing takes minutes, but a two-hour post-dose monitoring period is required, and you can’t drive again until the next day, after a restful night’s sleep.
Sources
- U.S. Food and Drug Administration. SPRAVATO (esketamine) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf
- Guimarães Pereira, J.E., et al. (2022). Efficacy and Safety of Ketamine in the Treatment of Neuropathic Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Pain Research. https://pmc.ncbi.nlm.nih.gov/articles/PMC9007468/
- Zhou, Y., et al. (2023). Sustained-Release Esketamine Based Nanoparticle-Hydrogel Delivery System for Neuropathic Pain Management. International Journal of Nanomedicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC10007983/
- Ketamine for Complex Regional Pain Syndrome: A Narrative Review Highlighting Dosing Practices and Treatment Response (2023). Anesthesiology Clinics. https://pmc.ncbi.nlm.nih.gov/articles/PMC10688501/
- Ma, X., et al. (2023). Application of Ketamine in Pain Management and the Underlying Mechanism. Pain Research and Management. https://pmc.ncbi.nlm.nih.gov/articles/PMC10447145/
- Daly, E.J., et al. (2019), summarized in: Use of SPRAVATO in Patients with Comorbid Anxiety or Obsessive-Compulsive Disorder. Janssen Medical Connect. https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-anxiety-or-obsessive-compulsive-disorder
- Johnson & Johnson. SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression (2025). https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
- Use of SPRAVATO in Pain. Janssen Medical Connect. https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-pain
Spravato near you in Dallas-Fort Worth. NeuroGlow gives Spravato at three REMS-certified clinics: Fort Worth (N Tarrant Pkwy, near Alliance; serving Keller, North Richland Hills and Southlake), McKinney (Virginia Pkwy; Frisco, Allen, Prosper and Plano, with evening and Saturday visits) and Flower Mound (Long Prairie Rd; Lewisville, Highland Village, Denton and Grapevine). Each session includes at least two hours of in-clinic monitoring. We check your insurance for free and handle prior authorization; see coverage facts. Spravato is FDA-approved for treatment-resistant depression and for depressive symptoms in major depressive disorder with acute suicidal ideation or behavior; it is not approved for chronic pain. A psychiatrist can talk through your options.
Considering Spravato in DFW? NeuroGlow bills BCBS of Texas, Aetna, Cigna, UnitedHealthcare, Humana, Medicare, Texas Medicaid (prior authorization required), TRICARE (administered in Texas by TriWest) and VA Community Care for Spravato at REMS-certified clinics in Fort Worth, McKinney and Flower Mound (coverage facts verified by our billing team on October 28, 2026). See if Spravato is right for you or call 469-218-4410.